However, acquired resistance to TKIs is one of the main obstacles to effective CML treatment and is involved in gene amplification of ABL tyrosine kinase point mutations [4]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.